The first 72 hours: managing pain and expected reactions

Some degree of pain, localised swelling, and stiffness in the treated knee is entirely normal in the hours and days after an Arthrosamid injection — and should be read as a procedural reaction rather than a sign that anything has gone wrong. Discomfort often increases once the local anaesthetic wears off, typically within the first day, so it is worth anticipating a short-term flare before any improvement begins.

For the first two to three days, the recommended approach is straightforward:

• Paracetamol for pain relief, taken regularly rather than only when discomfort peaks.
• Ibuprofen to reduce local inflammation alongside the paracetamol.
• NSAIDs may be continued for up to seven days post-procedure to help manage inflammation and support the early recovery environment.

If the clinical team has suggested it, Transcutaneous Electrical Nerve Stimulation (TENS) is a recognised adjunctive option for pain relief during this period; TENS units are available at MSK House for patients who have been advised to use one.

Joint effusion — a sensation of fullness or distension in the knee — is a recognised post-injection reaction. It does not indicate that the treatment has failed. Short-term symptom flares in the first 72 hours are a routine part of the procedural response and are separate from how the hydrogel will ultimately perform once it has integrated.

The 14-day rest rule and why it exists

Fourteen days of relative rest is the central aftercare instruction — framed in the official guidance as an instruction to 'be deliberately lazy' — and the reason is mechanistic rather than precautionary habit.

Arthrosamid is a non-biodegradable hydrogel (2.5% cross-linked polyacrylamide in 97.5% water) that does not dissolve or break down once injected. Instead, it embeds itself into the synovial membrane lining the joint capsule, where it acts as a structural scaffold. That integration process takes time. If the knee is subjected to heavy or repetitive loading too soon, there is a real risk of displacing the hydrogel before it has anchored properly — which would undermine the treatment before it has had any meaningful chance to work.

Relative rest does not mean complete immobility. Gentle movement around the home — walking to the kitchen, climbing stairs carefully, light activity of daily life — is generally acceptable and preferable to staying completely still. What the 14-day window is designed to prevent is anything that places sustained or high-impact demand on the joint: gym sessions, running, cycling, heavy manual work, or any sport that involves loading, pivoting, or impact through the knee.

If there is a specific activity you are unsure about — whether it falls on the acceptable or inadvisable side of that line — the right course is to ask the clinical team directly. They can advise based on your individual procedure, your baseline function, and how the knee is responding in the days after injection.

Week 4 onwards: when meaningful improvement typically begins

Around week 4 is when patients most commonly begin to notice a meaningful reduction in knee pain — not on the day of the injection, and not during the first fortnight of rest. Understanding this timeline prevents a common and understandable misreading: if the knee still feels much the same at the end of the 14-day integration period, that is not evidence the treatment has failed. The hydrogel is embedded; the benefit simply takes longer to establish.

This creates a three-phase shape to early recovery: immediate symptom management in the first two to three days, a protected integration period through to day 14, and then a gradual onset of improvement beginning around week 4. Patients can usefully locate themselves along this arc — particularly during the integration phase, when the knee may feel little different from before the procedure.

How much improvement patients ultimately experience varies by individual profile. A 24-month cohort study of 314 treated knees found that older patients, those without diabetes, those with lower-grade osteoarthritis, and those with bilateral knee involvement were more likely to reach a clinically meaningful improvement threshold on validated outcome measures. These factors may influence the degree of response — but they do not define an absolute ceiling for any one individual, and patients outside this profile have responded well in clinical series.

Progression beyond the 14-day rest period — how quickly to build activity and what level of loading the knee can tolerate — is best assessed against each person's actual clinical response rather than a universal timetable.

Physiotherapy after Arthrosamid: what it adds and what it covers

Physiotherapy is not included in the standard Arthrosamid package price and needs to be arranged separately — a practical point worth raising before or at the six-week follow-up appointment, at which point onward referral can be discussed if appropriate.

No Arthrosamid-specific phased rehabilitation protocol exists in the published clinical literature, so no week-by-week exercise plan should be expected. What physiotherapy for knee osteoarthritis generally targets — quadriceps strength, joint stability, and proprioception — remains directly relevant after an injection therapy. A stronger quadriceps reduces compressive load through the joint; better proprioception improves movement control and reduces the risk of compensatory gait patterns. Neither benefit is delivered by the injection itself, which addresses pain and the synovial environment rather than muscle function or neuromuscular coordination.

Timing matters. Physiotherapy exercises that load the knee should not begin until the 14-day integration period is complete, and even after that window, the pace and content of any programme should be confirmed with the treating clinician based on how the knee is actually responding. Starting too soon, or progressing too quickly, risks placing load on a joint that has not yet fully stabilised after the procedure.

The six-week review is the natural point to agree a physiotherapy plan — what it should cover, whether formal referral is advisable, and how it fits alongside the treatment's continuing effect. Patients who want to raise this sooner can do so directly through the clinic team.

The six-week review and returning to activity

The six-week follow-up, included as standard in the Arthrosamid treatment package, is the first structured point at which the treating clinician can formally assess treatment response and map out what comes next for each patient's knee.

Coming to that appointment with a clear account of how symptoms have shifted since around week 4 — where the pain sits now compared with before the injection, whether stiffness has changed, and how daily activity has felt — gives the clinician genuinely useful information to work with.

Return to higher-impact activity — sport, swimming, or gym exercise beyond gentle movement — does not follow a universal timetable. The published clinical literature does not specify these milestones for Arthrosamid, and any specific return-to-activity targets should be agreed at the review based on the individual's clinical picture. The same appointment is the appropriate moment to finalise a physiotherapy plan if one has not already been arranged.

If swelling, pain, or a sensation of joint distension worsens unexpectedly before the six-week mark, the clinical team should be contacted earlier rather than waiting for the scheduled appointment.

For patients who have not yet had an initial assessment and are considering Arthrosamid or another injection therapy for knee osteoarthritis, Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral — lincolnshireknee.co.uk.

Long-term durability: what the evidence shows at 3 and 5 years

Published data on Arthrosamid's long-term performance is more substantial than for most intra-articular treatments. A five-year extension of a randomised controlled trial — 58 participants completing the full period — recorded a mean WOMAC pain improvement of −16.2 points (95% CI: −20.0 to −12.4; p<0.0001) sustained through year 5, with no adverse events in that phase attributed to the device. A separate three-year RCT extension (75 completers) found a mean WOMAC pain reduction of −13.1 at year 3 (p<0.0001), again with no iPAAG-related serious adverse events between years one and three. Across a systematic review pooling 463 patients, statistically significant efficacy was consistently observed at 52 weeks and 13 months.

The comparator picture reinforces the durability point without overstating it. At 12 months, VAS pain scores in both the hyaluronic acid and corticosteroid groups had returned to baseline; the iPAAG group remained modestly improved. At six months, iPAAG outperformed corticosteroid (p<0.001); at one year, efficacy was broadly comparable with hyaluronic acid.

A 24-month cohort study of 314 knees reported that 155 developed what the authors categorised as complications. This figure warrants careful reading: the study captures expected procedural reactions — such as transient post-injection pain flares or temporary joint swelling of the kind described in standard aftercare — rather than serious device-related harm. No serious adverse events were attributed to iPAAG across any of the long-term studies cited.

Individual responses do vary. Older patients, those with lower-grade osteoarthritis, and those without diabetes were more likely to reach clinically meaningful improvement thresholds in the cohort data. The durability evidence provides a reasonable basis for confidence; it does not guarantee a specific outcome for any individual knee.

1. [1] Effectiveness and safety of polyacrylamide hydrogel injection for knee osteoarthritis: results from a 12-month follow up of an open-label study. (2024). https://doi.org/10.1186/s13018-024-04756-2 https://doi.org/10.1186/s13018-024-04756-2
2. [2] Three-year follow-up from a randomised controlled trial of a single intra-articular polyacrylamide hydrogel injection in subjects with knee osteoarthritis. (2025). https://doi.org/10.55563/clinexprheumatol/5lofry https://doi.org/10.55563/clinexprheumatol/5lofry
3. [3] Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24 month cohort study. (2025). https://doi.org/10.1016/j.jcot.2025.103136 https://doi.org/10.1016/j.jcot.2025.103136
4. [4] Sustained symptom relief and safety over five years following a single intra-articular injection of 2.5% polyacrylamide hydrogel in patients with knee osteoarthritis. (2025). https://doi.org/10.55563/clinexprheumatol/bsper8 https://doi.org/10.55563/clinexprheumatol/bsper8
5. [5] A prospective, open-label, clinical investigation of a single intra-articular polyacrylamide hydrogel injection in participants with knee osteoarthritis: a 5-year extension study. (2025). https://doi.org/10.1186/s13018-025-06526-0 https://doi.org/10.1186/s13018-025-06526-0
6. [6] Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. (2025). https://doi.org/10.1097/MD.0000000000044655 https://doi.org/10.1097/MD.0000000000044655